Cui Yuying, Wen Yu, Lv Chao, Zhao Dongmei, Yang Yu, Qiu Hongbin, Wang Chennan
School of Basic Medicine, Jiamusi University, Jiamusi, Heilongjiang 154007, P.R. China.
School of Clinical Medicine, Jiamusi University, Jiamusi, Heilongjiang 154007, P.R. China.
Mol Med Rep. 2023 Mar;27(3). doi: 10.3892/mmr.2023.12954. Epub 2023 Feb 17.
Subsequently to the publication of this paper, the authors have realized that they included the incorrect data in Fig. 5 for the p21 blots on p. 8. The corrected version of Fig. 5, featuring the data that were intended to have been included in this figure for the p21 blots, is shown on the next page. Furthermore, the authors wish to make the following changes to the text in the paper (changes are highlighted in bold): i) on p. 2, left‑hand column, line 16, the final sentence in the penultimate paragraph of the Introduction should have read as: "However, the functions of IGF2BP2, and the interactions between IGF2BP2 and NT5DC2 in DLBCL remain to be explored."; ii) In the Materials and methods section, subsection "", the first sentence should be revised to: "An RNA pull down kit (cat. no. P0202: Geneseed) was used to perform RNA pull down assay according to the manufacturer's instructions."; iii) In the Results section on p. 3, the subsection ".", the second sentence should be revised as follows: "mRNA and protein expression of NT5DC2 was highest in OCI‑Ly7 cells compared with that in the other DLBC cell lines (Fig. 1A)."; iv) The first two sentences in the following paragraph should have read as follows: "mRNA and protein expression levels of NT5DC2 were decreased in DLBC cells transfected with shRNA‑NT5DC2#1/2 compared with , and were lower in compared with the shRNA‑NT5DC2#1 group (Fig. 1B)."; and v) On p. 7, left‑hand column, the sentence commencing on line 59 should have read as: "The present results indicated that NT5DC2 was increased in DLBCL cells...". Note that these errors did not significantly affect either the results or the conclusions reported in this paper, and all the authors agree with the publication of this corrigendum. Furthermore, the authors thank the Editor of for allowing them the opportunity to publish this corrigendum, and apologize to the readership for any inconvenience caused. [Molecular Medicine Reports 26: 286, 2022; DOI: 10.3892/mmr.2022.12802].
在本文发表之后,作者们意识到他们在第8页图5的p21印迹中包含了错误的数据。图5的更正版本在下一页,其中展示了原本打算纳入该图的p21印迹数据。此外,作者们希望对论文中的文本进行以下修改(修改内容用粗体突出显示):i)在第2页左栏第16行,引言倒数第二段的最后一句话应改为:“然而,IGF2BP2的功能以及IGF2BP2与NT5DC2在弥漫性大B细胞淋巴瘤中的相互作用仍有待探索。”;ii)在“材料与方法”部分的“”小节中,第一句话应修改为:“使用RNA下拉试剂盒(产品编号P0202:Geneseed)按照制造商的说明进行RNA下拉实验。”;iii)在第3页的“结果”部分的“.”小节中,第二句话应修改如下:“与其他弥漫性大B细胞淋巴瘤细胞系相比,NT5DC2的mRNA和蛋白表达在OCI-Ly7细胞中最高(图1A)。”;iv)下一段的前两句话应改为如下内容:“与相比,用shRNA-NT5DC2#1/2转染的弥漫性大B细胞淋巴瘤细胞中NT5DC2的mRNA和蛋白表达水平降低,并且与shRNA-NT5DC2#1组相比,中更低(图1B)。”;v)在第7页左栏,从第59行开始的句子应改为:“目前的结果表明弥漫性大B细胞淋巴瘤细胞中NT5DC2增加……”。请注意,这些错误并未对本文报道的结果或结论产生重大影响,所有作者均同意发表本勘误。此外,作者们感谢《分子医学报告》的编辑给予他们发表本勘误的机会,并就由此给读者带来的不便表示歉意。[《分子医学报告》26: 286, 2022;DOI: 10.3892/mmr.2022.12802]